Dexamethasone shows promise in treatment of severely ill COVID-19 patients: All you need to know about the steroid drug
FirstpostThe Oxford University announced that dexamethasone, a common steroid drug, has shown promise in the treatment of severely ill COVID-19 patients by improving their survival rate by at least 20 percent The Oxford University announced that dexamethasone, a common steroid drug, has shown promise in the treatment of severely ill COVID-19 patients by improving their survival rate by at least 20 percent. Shortly after the announcement, the government of the UK reportedly announced that the drug would be authorised for the treatment of COVID-19 patients who are on ventilators or receiving oxygen therapy. Congratulating the UK government, researchers and all others involved, WHO’s director-general Dr Tedros Adhanom Ghebreyesus said in a press release on Tuesday that this is great news as it is “the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support”. According to the WHO, dexamethasone is a corticosteroid drug that has been used since the 1960s to treat inflammatory conditions like asthma, atopic dermatitis and conditions of the gut, liver, kidneys and endocrine system and certain cancers.